Veracyte (VCYT) Operating Expenses: 2012-2025
Historic Operating Expenses for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $68.3 million.
- Veracyte's Operating Expenses rose 2.00% to $68.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.6 million, marking a year-over-year increase of 2.22%. This contributed to the annual value of $282.0 million for FY2024, which is 10.61% down from last year.
- Per Veracyte's latest filing, its Operating Expenses stood at $68.3 million for Q3 2025, which was down 28.10% from $95.0 million recorded in Q2 2025.
- In the past 5 years, Veracyte's Operating Expenses ranged from a high of $100.3 million in Q4 2023 and a low of -$35.1 million during Q4 2022.
- Over the past 3 years, Veracyte's median Operating Expenses value was $74.6 million (recorded in 2024), while the average stood at $79.0 million.
- In the last 5 years, Veracyte's Operating Expenses slumped by 144.10% in 2022 and then soared by 385.43% in 2023.
- Quarterly analysis of 5 years shows Veracyte's Operating Expenses stood at $79.7 million in 2021, then slumped by 144.10% to -$35.1 million in 2022, then skyrocketed by 385.43% to $100.3 million in 2023, then declined by 25.64% to $74.6 million in 2024, then grew by 2.00% to $68.3 million in 2025.
- Its last three reported values are $68.3 million in Q3 2025, $95.0 million for Q2 2025, and $76.6 million during Q1 2025.